Novo Nordisk Stock Falls After Weight Loss Drug Data

Novo Nordisk's stock dropped significantly after new data showed its experimental weight-loss drug Cagrisema was less effective than Eli Lilly's tirzepatide.

23 Feb, 09:49 — 23 Feb, 09:49

Post Share

ℹOnly 1 source covers this story

Read at source (1 outlet)

berlingske8h ago

Novo Nordisk-aktie falder efter ny data om vægttabshåb

Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder.

Read full article →

PERSPECTA

PERSPECTA

Novo Nordisk Stock Falls After Weight Loss Drug Data

Read at source (1 outlet)

Novo Nordisk-aktie falder efter ny data om vægttabshåb

Related Stories

Joint Inspection Held for Proposed Elevated Rotary Flyover at IOC Junction

Lukavac Coking Plant Closure a Major Loss for BiH Industry and Workers

Hobart stadium power options uncosted, not finalised

Citi Nears Sale of Banamex Shares to Blackstone and Other Investors

PERSPECTA